Fabry disease: Percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male

Sudheera Magage, Ales Linhart, Jan Bultas, Jan Vojacek, Martin Mates, Tomas Palecek, Jana Popelová, Jaroslav Tintera, Michael Aschermann, Martin E. Goldman, Robert J. Desnick

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Fabry disease (α-galactosidase A deficiency) is an X-linked recessive lysosomal storage disease in which left ventricular hypertrophy (LVH) is common, and if severe, may mimic hypertrophic obstructive cardiomyopathy. Alcohol-induced percutaneous transluminal septal myocardial ablation (PTSMA) has been used as a safe and effective method to alleviate LVH obstruction in patients with hypertrophic obstructive cardiomyopathy (HCM). We describe a case of a classically affected Fabry 53-year-old male with symptomatic HCM (NYHA class III with exertional angina) who was treated with PTSMA. The procedure safely and effectively alleviated symptomatic left ventricular outflow tract obstruction at long-term follow-up, and the patient's NYHA classification was reduced to NYHA class I to II.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalEchocardiography
Volume22
Issue number4
DOIs
StatePublished - Apr 2005

Keywords

  • Alcohol-induced percutaneous transluminal septal myocardial ablation
  • Fabry disease
  • Left ventricular hypertrophy
  • α-galactosidase A deficiency

Fingerprint

Dive into the research topics of 'Fabry disease: Percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male'. Together they form a unique fingerprint.

Cite this